? ? Lung disease is an important cause of morbidity and mortality at all ages. There is a pressing need for development and validation of biomarkers to aid in the diagnosis and management of patients with lung disease. In particular, combinations of protein biomarkers that can be obtained non-invasively offer great promise. We propose to establish a multidisciplinary Clinical Proteomics Center in Lung Disease to rapidly develop and validate panels of protein biomarkers that can be used in diagnosis, disease prognostication, and treatment of pediatric and adult lung disorders. ? We will base our program on large, well-characterized pediatric and adult patient populations, and extensive expertise in biomarker research. The Clinical Proteomics Program will consist of a phased model of biomarker development encompassing assay validation through retrospective and prospective clinical validation to large scale application. The phased development strategy has several advantages including careful, expeditious evaluation of novel biomarkers; reduction in panel size to the minimum that is clinically useful; and maximum utilization of previously existing national disease networks.
Our specific aims will be to: 1. Establish a center with five cores (Clinical, Laboratory, Data Management/Biostatistics, Educational, and Administrative) to select, validate, apply and continually improve protein biomarker panels. 2. Develop specific protein biomarker panels aimed at predicting progression of disease, assessing likelihood and significance of exacerbation, and evaluating response to treatment in Chronic Obstructive Pulmonary Disease, Asthma, Acute Lung Injury, Chronic Lung Disease of Infancy, Pulmonary Arterial Hypertension and Cystic Fibrosis. 3. Create a local and national educational and skills development program for MDs, PhDs, MD/PhDs, Laboratory Personnel and Research Coordinators, in Clinical Proteomics and 4. Establish a national resource for investigators interested in developing protein biomarkers of lung disease. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL081335-02
Application #
7110943
Study Section
Special Emphasis Panel (ZHL1-CSR-K (M1))
Program Officer
Gan, Weiniu
Project Start
2005-08-15
Project End
2009-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
2
Fiscal Year
2006
Total Cost
$1,030,926
Indirect Cost
Name
University of Colorado Denver
Department
Pediatrics
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Hopper, Rachel K; Abman, Steven H; Ivy, D Dunbar (2016) Persistent Challenges in Pediatric Pulmonary Hypertension. Chest 150:226-36
Laguna, Theresa A; Reilly, Cavan S; Williams, Cynthia B et al. (2015) Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation. Pediatr Pulmonol 50:869-77
Accurso, Frank J; Van Goor, Fredrick; Zha, Jiuhong et al. (2014) Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros 13:139-47
Wagner, Brandie D; Takatsuki, Shinichi; Accurso, Frank J et al. (2013) Evaluation of circulating proteins and hemodynamics towards predicting mortality in children with pulmonary arterial hypertension. PLoS One 8:e80235
Duncan, Mark; Wagner, Brandie D; Murray, Keri et al. (2012) Circulating cytokines and growth factors in pediatric pulmonary hypertension. Mediators Inflamm 2012:143428
Ratjen, Felix; Saiman, Lisa; Mayer-Hamblett, Nicole et al. (2012) Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 142:1259-1266
Laguna, Theresa A; Wagner, Brandie D; Starcher, Barry et al. (2012) Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation. Pediatr Pulmonol 47:856-63
Szefler, Stanley J (2011) Advancing asthma care: the glass is only half full! J Allergy Clin Immunol 128:485-94
Szefler, Stanley J; Dakhama, Azzeddine (2011) New insights into asthma pathogenesis and treatment. Curr Opin Immunol 23:801-7
Cooley, J; Sontag, M K; Accurso, F J et al. (2011) SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition. Eur Respir J 37:1083-90

Showing the most recent 10 out of 45 publications